Coherus BioSciences (NASDAQ:CHRS) PT Lowered to $8.00 at Barclays

Coherus BioSciences (NASDAQ:CHRS – Get Rating) had its price objective decreased by Barclays from $13.00 to $8.00 in a research report released on Tuesday, The Fly reports.

A number of other analysts have also weighed in on CHRS. Mizuho upped their price objective on shares of Coherus BioSciences from $21.00 to $23.00 in a research note on Tuesday, March 14th. Truist Financial initiated coverage on shares of Coherus BioSciences in a research note on Monday, May 1st. They issued a buy rating and a $24.00 price target on the stock. StockNews.com initiated coverage on shares of Coherus BioSciences in a research note on Thursday, May 18th. They issued a hold rating on the stock. HC Wainwright dropped their price target on shares of Coherus BioSciences from $26.00 to $24.00 in a research note on Tuesday, May 9th. Finally, Maxim Group decreased their price objective on Coherus BioSciences from $15.00 to $12.00 in a report on Friday, May 12th. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, Coherus BioSciences has a consensus rating of Moderate Buy and a consensus target price of $16.14.

Coherus BioSciences Trading Down 1.2 %

Shares of NASDAQ CHRS opened at $4.29 on Tuesday. The firm has a 50 day moving average of $6.66 and a 200 day moving average of $7.31. The firm has a market capitalization of $345.56 million, a price-to-earnings ratio of -1.23 and a beta of 0.95. Coherus BioSciences has a 12-month low of $4.16 and a 12-month high of $14.11.

Coherus BioSciences (NASDAQ:CHRS – Get Rating) last released its earnings results on Monday, March 6th. The biotechnology company reported ($0.76) EPS for the quarter, missing the consensus estimate of ($0.64) by ($0.12). The firm had revenue of $45.35 million for the quarter, compared to analysts’ expectations of $45.72 million. During the same quarter in the previous year, the business earned ($0.60) earnings per share. Sell-side analysts predict that Coherus BioSciences will post -2.05 EPS for the current year.

Institutional Trading of Coherus BioSciences

Hedge funds and other institutional investors have recently modified their holdings of the business. BlackRock Inc. grew its position in shares of Coherus BioSciences by 2.2% during the first quarter. BlackRock Inc. now owns 14,397,565 shares of the biotechnology company’s stock worth $98,479,000 after buying an additional 315,269 shares in the last quarter. State Street Corp lifted its stake in Coherus BioSciences by 23.6% during the second quarter. State Street Corp now owns 6,383,103 shares of the biotechnology company’s stock worth $46,214,000 after purchasing an additional 1,218,951 shares during the last quarter. Alliancebernstein L.P. lifted its stake in Coherus BioSciences by 1.8% during the fourth quarter. Alliancebernstein L.P. now owns 6,217,558 shares of the biotechnology company’s stock worth $49,243,000 after purchasing an additional 110,697 shares during the last quarter. Vanguard Group Inc. lifted its stake in Coherus BioSciences by 7.1% during the third quarter. Vanguard Group Inc. now owns 5,228,701 shares of the biotechnology company’s stock worth $50,248,000 after purchasing an additional 345,286 shares during the last quarter. Finally, Aristotle Capital Boston LLC lifted its stake in Coherus BioSciences by 8.0% during the first quarter. Aristotle Capital Boston LLC now owns 2,254,102 shares of the biotechnology company’s stock worth $15,418,000 after purchasing an additional 167,528 shares during the last quarter. 99.45% of the stock is owned by institutional investors and hedge funds.

About Coherus BioSciences

(Get Rating)

Coherus BioSciences, Inc is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of biosimilar therapeutics. Its products include UDENYCA and Coherus COMPLETE. The company was founded by Dennis M. Lanfear, Stuart E. Builder, Dr. Alan Herman, Doug Farrar and Steve Glover in September 2010 and is headquartered in Redwood City, CA.